| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/29/2009 | US20090029392 Magnetic-nanoparticle conjugates and methods of use |
| 01/29/2009 | US20090029361 Growth differentiation factor-7 |
| 01/29/2009 | US20090028966 Methods for Introducing Reactive Secondary Amines Pendant to Polymers Backbones that are Useful for Diazeniumdiolation |
| 01/29/2009 | US20090028938 Dosage forms with improved bioavailability |
| 01/29/2009 | US20090028922 Local Delivery Method and Composition |
| 01/29/2009 | US20090028904 Novel cochleate formulations |
| 01/29/2009 | US20090028893 Methods for producing fusion polypeptides or enhancing expression of fusion polypeptides |
| 01/29/2009 | US20090028890 encodes an HIV-1 MA polypeptide myristate binding site; capable of selectively eliciting a substantially th-1 immune response to HIV-1; vaccine |
| 01/29/2009 | US20090028814 High molecular weight medicine-containing preparation in powder form for administration through mucosa |
| 01/29/2009 | US20090028807 Composition comprising a polycondensate, method of treatment, polycondensate, and method of preparation |
| 01/29/2009 | US20090025713 Nebulised Antibiotics for Inhalation Therapy |
| 01/29/2009 | CA2720628A1 Fusion proteins |
| 01/29/2009 | CA2694386A1 Medicament for transdermal use on animals |
| 01/29/2009 | CA2694343A1 Resveratrol complex and process for the preperation |
| 01/29/2009 | CA2694083A1 Antigen-adjuvant compositions and methods |
| 01/29/2009 | CA2693888A1 Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| 01/29/2009 | CA2693663A1 A conjugate of an antibody against cd4 and antifusogenic peptides |
| 01/29/2009 | CA2693277A1 Immune modulation via c-type lectin |
| 01/29/2009 | CA2693155A1 Self coupling recombinant antibody fusion proteins |
| 01/28/2009 | EP2019122A1 Polymer conjugate of podophyllotoxin |
| 01/28/2009 | EP2018875A1 Poorly-water-soluble pharmaceutical agent |
| 01/28/2009 | EP2018869A1 Licorice polyphenol preparation |
| 01/28/2009 | EP2018866A1 Pharmaceutical compositions containing voriconazole |
| 01/28/2009 | EP2018853A1 Pharmaceutical compositions comprising a HMG COA reductase inhibitor |
| 01/28/2009 | EP2018852A1 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 01/28/2009 | EP2018403A1 Water dispersible films for delivery of active agents to the epidermis |
| 01/28/2009 | EP2018186A2 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
| 01/28/2009 | EP2018160A2 Modified release formulations containing drug-ion exchange resin complexes |
| 01/28/2009 | EP2018154A1 Hydrogel suspension and manufacturing process thereof |
| 01/28/2009 | EP2018152A2 Pre-mixed, ready-to-use pharmaceutical compositions |
| 01/28/2009 | EP2018150A1 Pharmaceutical composition having reduced abuse potential |
| 01/28/2009 | EP1715851B1 Consumer customized dosage forms |
| 01/28/2009 | EP1648473B1 Single dose fast dissolving azithromycin |
| 01/28/2009 | EP1470826B1 Decoy-containing pharmaceutical compositions for the treatment of aneurysms |
| 01/28/2009 | CN101356269A Methods for expression and purification of recombinant human growth hormone |
| 01/28/2009 | CN101355970A Peptide-DICER substrate RNA conjugates as delivery vehicles for SIRNA |
| 01/28/2009 | CN101355953A Promoter for recovery from anesthesia |
| 01/28/2009 | CN101355931A Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect |
| 01/28/2009 | CN101355927A Film-coated and/or granulated calcium-containing compounds and use thereof in pharmaceutical compositions |
| 01/28/2009 | CN101353784A Method for coating target medicament particle with soft magnetic nanofilm |
| 01/28/2009 | CN101353647A Simulating retrovirus of target tumor, and preparation and use thereof |
| 01/28/2009 | CN101353475A Preparation of aquagel material having thermal sensitivity and reactivity |
| 01/28/2009 | CN101353379A Protein modified biological-inorganic nano composite material and preparation thereof |
| 01/28/2009 | CN101352574A Target polypeptide-gold/silicon dioxide nano complex particle and synthesis thereof |
| 01/28/2009 | CN101352573A Recombinant human granulocyte colony stimulating factor lysine defect body modified by polyethyleneglycol |
| 01/28/2009 | CN101352572A Method for preparing folacin-carboxyl complexes |
| 01/28/2009 | CN101352544A Carrier gel for treating gout |
| 01/28/2009 | CN101352494A Children's granules for clearing heat and suppressing cough and preparation method thereof |
| 01/28/2009 | CN101352486A Isatis root and astragalus microspheres for injections and preparation method thereof |
| 01/28/2009 | CN101352449A Vitamin orally disintegrating tablet and preparation method thereof |
| 01/28/2009 | CN101352441A Brimonidine tartrate in situ forming eye gel |
| 01/28/2009 | CN101352440A Guaifenesin, pseudoephedrine hydrochloride and dextromethorphan hydrobromide sustained-release preparation and preparation method thereof |
| 01/28/2009 | CN101352439A Composition injection containing tetrandrine and preparation method thereof |
| 01/28/2009 | CN101352428A Solid preparation containing ibuprofen and tranexamic acid |
| 01/28/2009 | CN101352426A Osmotic pump controlled release preparation composition and preparation thereof |
| 01/28/2009 | CN101352425A Compound osmotic pump controlled release preparation and preparation method thereof |
| 01/28/2009 | CN101352421A Method for preparing basically non-crystalline type telmisartan |
| 01/28/2009 | CN101352414A Compound anticancer sustained-release injection containing vascular inhibitor |
| 01/28/2009 | CN101352412A Intestinal-lysis non-steroidal antipyretic-antalgic anti-inflammatory agent and preparation thereof |
| 01/28/2009 | CN101352410A Prescription and method for making oil liquid or water-containing viscous liquid into solid dosage form |
| 01/28/2009 | CN101352409A Diclofenac sodium in situ forming eye gel |
| 01/28/2009 | CN101352365A Positioner for fixing micro organs |
| 01/28/2009 | CN101352234A Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 01/28/2009 | CN100455597C Process of high purity albumin production |
| 01/28/2009 | CN100455298C Gymnema sylvestre total saponin inclusion compound and its prepn process |
| 01/28/2009 | CN100455288C Formula of Reynoldazine hydrochloride prepn. |
| 01/28/2009 | CN100455287C Formulations |
| 01/28/2009 | CN100455286C Injection of palonosetron and preparation process thereof |
| 01/28/2009 | CN100455282C Process for producing medicine |
| 01/28/2009 | CN100455278C Compositions for the preparation of carbon dioxide gel for external use and carbon dioxide gels for external use |
| 01/27/2009 | US7482483 calixarenes having acyclic isophthalic acid groups attached, used as target for platelet derived growth factors or vascular endothelial growth factors; angiogenesis inhibitors, antiproliferative, antitumor or anticarcinogenic agents |
| 01/27/2009 | US7482383 Emulsion containing a plant extract, method for producing said emulsion and for obtaining said plant extract |
| 01/27/2009 | US7482381 For use in actuating or drug delivery devices containing an artificial muscle valve and micropump that controls the release of therapeutic fluids including implantable platforms |
| 01/27/2009 | US7482377 Administering an immediate release oral dosage of diclofenac or in salt form together with one or more alkali metal bicarbonates in an amount of >20% by weight; palatable and free from any unpleasant taste or side effects; short time to the maximum plasma concentration; high maximum plasma concentration |
| 01/27/2009 | US7482376 Conjugated complement cascade inhibitors |
| 01/27/2009 | US7482319 delivery of enzyme, a pharmaceutical agent, a plasmid, a polynucleotide, a polypeptide, a sensor to an organism, tissue or cell by incorporting into a vault like particle such as polypeptide, linked to MVP, VPARP, a portion of VPARP, or a modified MVP, VPARP; adminstering |
| 01/27/2009 | US7482160 Process of making a compound by forming a polymer from a template drug |
| 01/27/2009 | US7482147 polypeptides, proteins or fusion proteins having hydrolase enzyme activity, used for medical diagnosis and therapy |
| 01/27/2009 | US7482115 Bacteriophage; antibiotics or bacteriostatic agents for treatment of antibiotic-resistant infections; medical equipment |
| 01/27/2009 | US7482031 Development of an anti-cough, anti-tussive and throat soothing herbal formulation |
| 01/27/2009 | US7482024 highly dispersible mixture of drugs and dipeptides or tripeptides, in the form of liquids, aerosols or powders, administered by inhalation |
| 01/27/2009 | US7482022 Palatable chewable tablet |
| 01/27/2009 | US7482020 for making an adjuvanted vaccine comprising host albumin. The process comprises mixing host serum or host serum with an antigen, and then mixing the resulting mixture with an adjuvant. |
| 01/27/2009 | US7482018 Using hydrophilic surfactant; encapsulated hydrophobic drug |
| 01/27/2009 | US7482013 Albumin fusion proteins |
| 01/27/2009 | CA2523989C Biodegradable branched polylactide derivatives capable of forming polymeric micelles, and their preparation method and use |
| 01/27/2009 | CA2489407C Lasofoxifene tablet and its coating |
| 01/27/2009 | CA2474701C Preparation of biodegradeable microparticles containing a biologically active agent |
| 01/27/2009 | CA2466808C Formulations for use in medical or diagnostic procedures |
| 01/27/2009 | CA2438168C Modulated release particles for aerosol delivery |
| 01/27/2009 | CA2416403C A medicinal aerosol formulation |
| 01/27/2009 | CA2399856C Antibiotic composition with inhibitor |
| 01/27/2009 | CA2395226C Devices for the delivery of drugs having antiprogestinic properties |
| 01/27/2009 | CA2380783C Human monoclonal antibodies to prostate specific membrane antigen |
| 01/27/2009 | CA2380757C Pharmaceutical agent comprising a benzamide derivative as active ingredient |
| 01/27/2009 | CA2378385C Patch formulation for external use including an acid addition salt of a basic drug |
| 01/27/2009 | CA2360248C Combinations of formoterol and a tiotropium salt |
| 01/27/2009 | CA2354034C Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period |
| 01/27/2009 | CA2350894C Methods for preparing coated drug particles and pharmaceutical formulations thereof |
| 01/27/2009 | CA2348451C Dosage forms containing taste masked active agents |